Previous 10 | Next 10 |
COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced it will present a poster on the performance of its lead investig...
Ligand Pharmaceuticals (LGND) share price has fallen more than 50% since September, and on January 16, Citron Research published a report questioning the credibility of Ligand's pipeline data and optimism, which led to another sharp decline of the share price. However, the share price recove...
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 64 Performance Each week, since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is ...
Event to feature business updates and presentations by four corporate partners Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, March 12, 2019 from 10:00 a.m. to 12:00 p.m. Eastern time (7:00 a.m. to 9:00 a.m. Pacific time) in New York City. ...
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 64 Performance Each week, since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is ...
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology looks undervalued by a bit more than 10% relative to historical avera...
Ligand Pharmaceuticals Incorporated (LGND) Q4 2018 Results Earnings Conference Call February 07, 2019, 04:30 PM ET Company Participants Todd Pettingill - Director, Corporate Development and Investor Relations John Higgins - Chief Executive Officer Matthew Foehr - President and Ch...
Ligand Pharmaceuticals (NASDAQ: LGND ) Q4 results ($M): Revenues: 59.6 (+18.0%); Royalties: 40.2 (+42.0%). More news on: Ligand Pharmaceuticals Incorporated, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Ligand Pharmaceuticals (NASDAQ: LGND ): Q4 Non-GAAP EPS of $1.70 beats by $0.48 ; GAAP EPS of -$2.02 misses by $2.92 . More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Conference Call Begins at 4:30 p.m. Eastern Time Today Analyst day to be held on Tuesday March 12 at 10:00 a.m. Eastern Time in New York City Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2018...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-08-02 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...